机器人辅助前列腺根治术后生化持续患者的PSMA PET/CT肿瘤定位
该回顾性研究纳入150例机器人辅助腹腔镜根治性前列腺切除(RARP)后生化持续(BCP)患者,评估18F-DCFPyL或68Ga-PSMA-11 PET/CT的病灶检出情况。结果显示67%患者存在PSMA表达病灶,59%存在前列腺窝外病灶,26%存在盆腔外病灶;术后较高PSA值(P=0.004)和病理淋巴结阳性(P=0.006)是前列腺窝外转移的独立预测因素。
要点
- BCP患者中PSMA PET/CT病灶检出率高,多数已有前列腺窝外或远处转移。
- 术后较高PSA值和病理淋巴结阳性与前列腺窝外转移独立相关。
- BCP患者应行PSMA PET/CT以指导挽救治疗策略。
核心结论
- BCP患者中高比例已存在盆腔淋巴结转移或远处转移,PSMA PET/CT有助指导挽救治疗。
研究设计与样本
- 回顾性评估150例RARP后BCP患者,BCP定义为术后至少6周首次血清PSA≥0.1 ng/mL且术后从未不可测。
- 采用18F-DCFPyL或68Ga-PSMA-11 PET/CT显像,并行多变量逻辑回归分析前列腺窝外转移(≥miN1)的预测因素。
主要发现
- 150例中101例(67%)PET/CT见PSMA表达病灶。
- 150例中89例(59%)见前列腺窝外PSMA表达增高病灶。
- 150例中39例(26%)见盆腔外PSMA阳性病灶。
- 多变量分析显示术后较高PSA值(P=0.004)和病理淋巴结阳性(P=0.006)是≥miN1的独立预测因素。
关键数值与推荐
- BCP定义:RARP后至少6周首次血清PSA≥0.1 ng/mL,且术后无不可测PSA值。
- PSMA PET/CT显像中位PSA值为0.60 ng/mL(四分位距0.3-2.4),中位术后6个月(四分位距4-10)进行。
临床怎么用
- 对RARP后BCP患者,应考虑行PSMA PET/CT以明确病灶分布并指导挽救治疗。
- 术后PSA较高或病理淋巴结阳性的BCP患者,前列腺窝外转移风险更高,更应行PSMA PET/CT评估。
局限性
- 回顾性研究设计。
- 未报告诊断准确性指标(如敏感度、特异度)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Since the introduction of radiolabeled prostate-specific membrane antigen (PSMA) PET/CT, the ability to visualize recurrent prostate cancer has improved substantially. However, diagnostic accuracy is largely lacking for radiolabeled PSMA PET/CT in patients with biochemical persistence (BCP; that is, persistently measurable prostate-specific antigen [PSA] values after robot-assisted laparoscopic radical prostatectomy [RARP]). Therefore, the aim of this study was to determine the role of PSMA (i.e.,18F-DCFPyL or 68Ga-PSMA-11) PET/CT imaging in patients who experience BCP after RARP and to evaluate the sites of persistent disease on PSMA PET/CT. Methods: In total, 150 consecutive patients with BCP after RARP who underwent radiolabeled PSMA PET/CT imaging were retrospectively evaluated. BCP was defined as any detectable first serum PSA value after RARP (≥0.1 ng/mL) at least 6 wk after surgery, in the absence of an undetectable PSA value after RARP. A multivariable logistic regression analysis was performed to identify predictors for the detection of metastases outside the prostatic fossa (≥miN1) on PSMA PET/CT. Results: PSMA PET/CT was performed at a median PSA value of 0.60 ng/mL (interquartile range, 0.3-2.4) after a median of 6 mo (interquartile range, 4-10) after RARP. In total, 101 of 150 patients (67%) had lesions with PSMA expression on PET/CT, and 89 of 150 (59%) had lesions with increased PSMA expression sites outside the prostatic fossa. Moreover, 39 of 150 patients (26%) had PSMA-positive lesions outside the pelvis. On multivariable analysis, higher PSA values after RARP (P = 0.004) and positive pathologic lymph node status (P = 0.006) were independent predictors for ≥miN1. Conclusion: In the presence of BCP, a high proportion of patients already had disease metastatic to the pelvic lymph nodes or showed evidence of distant metastases, as indicated by PSMA PET/CT. Higher PSA levels after RARP and positive pathologic lymph node status were significantly associated with metastases outside the prostatic fossa. In patients with BCP, PSMA PET/CT imaging is warranted to guide salvage treatment strategies.
引用
- Meijer D, Donswijk ML, Bodar YJL, et al. Biochemical Persistence of Prostate-Specific Antigen After Robot-Assisted Laparoscopic Radical Prostatectomy: Tumor Localizations Using PSMA PET/CT Imaging. J Nucl Med. 2020. PMID: 33158904. doi:10.2967/jnumed.120.252528
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。